Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

This study has been completed.

Sponsored by:	Innovative Medical
Information provided by:	Innovative Medical
ClinicalTrials.gov Identifier:	NCT00347841

Purpose

To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.

Condition	Intervention	Phase
Glaucoma	Drug: Bimatoprost 0.03%, Latanoprost	Phase IV

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma

Drug Information available for: Latanoprost Bimatoprost

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Active Control, Single Group Assignment
Official Title:	Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

· Male or female > 18 years of age
- Documented low-responder to latanoprost therapy as delineated in the outline above.
- Diagnosis of open-angle glaucoma or ocular hypertension
- Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria:

· Known contraindication to bimatoprost or any component of any study medication
- Uncontrolled systemic disease
- Active ocular disease other than glaucoma or ocular hypertension
- Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)
- History of intraocular surgery within the last 3 months

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00347841

Locations

United States, Pennsylvania
Dr. Noecker
Pittsburgh, Pennsylvania, United States, 15213

Sponsors and Collaborators

Innovative Medical

Investigators

Principal Investigator:

Robert Noecker, MD

UPMC Eye Center

More Information

Study ID Numbers:	5178
Study First Received:	June 30, 2006
Last Updated:	May 30, 2007
ClinicalTrials.gov Identifier:	NCT00347841
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Bimatoprost
Glaucoma
Eye Diseases

Latanoprost
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:

Therapeutic Uses
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009